Publications by authors named "Josh Bedel"
Background: In the phase 3 trial ARIEL3, maintenance treatment with the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib provided clinical benefit versus placebo for patients with recurrent, platinum-sensitive ovarian cancer. Here, we evaluate the impact of age on the clinical utility of rucaparib in ARIEL3.
Methods: Patients with platinum-sensitive, recurrent ovarian carcinoma with ≥2 prior platinum-based chemotherapies who responded to their last platinum-based therapy were enrolled in ARIEL3 and randomized 2:1 to rucaparib 600 mg twice daily or placebo.
Article Synopsis
- The study evaluates the effectiveness of rucaparib, a maintenance treatment for ovarian cancer, versus a placebo using metrics like quality-adjusted progression-free survival (QA-PFS) and quality-adjusted time without symptoms or toxicity (Q-TWiST).
- Results showed that patients on rucaparib had significantly longer mean QA-PFS and Q-TWiST compared to those on placebo, especially in specific genetic cohorts like the -mutant and homologous recombination deficient (HRD) groups.
- The findings suggest rucaparib not only prolongs life without disease progression but also improves the quality of life during those periods, making it a promising option for patients with recurrent ovarian cancer.